Celara Diagnostics Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 06-07-2024
- Paid Up Capital ₹ 4.05 Cr
as on 06-07-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 15.00 Cr
as on 06-07-2024
- Satisfied Charges ₹ 12.00 Cr
as on 06-07-2024
- Revenue 3.08%
(FY 2023)
- Profit 549.90%
(FY 2023)
- Ebitda 30.85%
(FY 2023)
- Net Worth 44.94%
(FY 2023)
- Total Assets -19.19%
(FY 2023)
About Celara Diagnostics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.05 Cr.
The company currently has active open charges totaling ₹15.00 Cr. The company has closed loans amounting to ₹12.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Prakash Satyanarayana and Radhesh Srinivasan serve as directors at the Company.
- CIN/LLPIN
U85320KA2017PTC103452
- Company No.
103452
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 May 2017
- Date of AGM
26 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Celara Diagnostics Private Limited offer?
Celara Diagnostics Private Limited offers a wide range of products and services, including Diagnostic Medical Imaging Equipment, Medical Imaging Machine & Accessories.
Who are the key members and board of directors at Celara Diagnostics?
Board Members(2)
Financial Performance and Corporate Structure Insights of Celara Diagnostics.
Celara Diagnostics Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.08% increase. The company also saw a substantial improvement in profitability, with a 549.9% increase in profit. The company's net worth Soared by an impressive increase of 44.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Celara Diagnostics?
In 2023, Celara Diagnostics had a promoter holding of 67.19% and a public holding of 32.81%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 03 Nov 2023 | ₹3.00 Cr | Open |
Others Creation Date: 29 Mar 2019 | ₹12.00 Cr | Open |
Others Creation Date: 15 Sep 2017 | ₹12.00 Cr | Satisfied |
How Many Employees Work at Celara Diagnostics?
Celara Diagnostics has a workforce of 105 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Sep 08, 2021, Celara Diagnostics has raised a total of ₹ 25.83 Cr, with the most recent deal valued at ₹ 2 Cr. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
